Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldenberg

Showing results (21-30 of 318) with videos related to

Pageof 32
Sort By:
Mabs|June 19, 2019
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecanDavid M Goldenberg, Robert M Sharkey
Molecular Cancer Therapeutics|February 20, 2007
Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenograftsAlice P Taylor, David M Goldenberg
Molecular Biotechnology|April 17, 2007
Methods and goals for the use of in vitro and in vivo chemosensitivity testingRosalyn D Blumenthal, David M Goldenberg
Advanced Drug Delivery Reviews|May 30, 2008
Use of antibodies and immunoconjugates for the therapy of more accessible cancersRobert M Sharkey, David M Goldenberg
Therapeutic Delivery|July 24, 2012
Recent progress in cancer therapy with radiolabeled monoclonal antibodiesDavid M Goldenberg, Robert M Sharkey
Thescientificworldjournal|October 19, 2010
New antibody conjugates in cancer therapySerengulam V Govindan, David M Goldenberg
Hospital Practice (1995)|October 5, 2010
Radioactive antibodies: a historical review of selective targeting and treatment of cancerDavid M Goldenberg, Robert M Sharkey
Immunotherapy|March 15, 2011
Cancer radioimmunotherapyRobert M Sharkey, David M Goldenberg
CA: a Cancer Journal for Clinicians|July 28, 2006
Targeted therapy of cancer: new prospects for antibodies and immunoconjugatesRobert M Sharkey, David M Goldenberg
Cancer Investigation|February 10, 2006
Advances in radioimmunotherapy in the age of molecular engineering and pretargetingRobert M Sharkey, David M Goldenberg
Pageof 32

Showing results (21-30 of 318) with videos related to

Sort By:
Pageof 32
Mabs|June 19, 2019
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecanDavid M Goldenberg, Robert M Sharkey
Molecular Cancer Therapeutics|February 20, 2007
Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenograftsAlice P Taylor, David M Goldenberg
Molecular Biotechnology|April 17, 2007
Methods and goals for the use of in vitro and in vivo chemosensitivity testingRosalyn D Blumenthal, David M Goldenberg
Advanced Drug Delivery Reviews|May 30, 2008
Use of antibodies and immunoconjugates for the therapy of more accessible cancersRobert M Sharkey, David M Goldenberg
Therapeutic Delivery|July 24, 2012
Recent progress in cancer therapy with radiolabeled monoclonal antibodiesDavid M Goldenberg, Robert M Sharkey
Thescientificworldjournal|October 19, 2010
New antibody conjugates in cancer therapySerengulam V Govindan, David M Goldenberg
Hospital Practice (1995)|October 5, 2010
Radioactive antibodies: a historical review of selective targeting and treatment of cancerDavid M Goldenberg, Robert M Sharkey
Immunotherapy|March 15, 2011
Cancer radioimmunotherapyRobert M Sharkey, David M Goldenberg
CA: a Cancer Journal for Clinicians|July 28, 2006
Targeted therapy of cancer: new prospects for antibodies and immunoconjugatesRobert M Sharkey, David M Goldenberg
Cancer Investigation|February 10, 2006
Advances in radioimmunotherapy in the age of molecular engineering and pretargetingRobert M Sharkey, David M Goldenberg
Pageof 32